<DOC>
	<DOCNO>NCT02062385</DOCNO>
	<brief_summary>This study ass efficacy , safety , immunogenicity 3-dose regimen RotaTeq™ ( V260 ) healthy Chinese infant . Approximately 4040 participant least 6 week 12 week age time first vaccination V260 placebo enrol randomize ( 1:1 ) receive either V260 placebo . Participants also receive routine China Expanded Program Immunization ( EPI ) vaccine ( oral poliovirus vaccine [ OPV ] diphtheria , tetanus , acellular pertussis vaccine [ DTaP ] ) either stagger concomitantly V260 placebo . All participant follow efficacy safety . Immune responses OPV DTaP evaluate subset participant . The primary hypothesis study state V260 efficacious prevent severity rotavirus gastroenteritis compare placebo .</brief_summary>
	<brief_title>Efficacy , Safety , Immunogenicity V260 Healthy Chinese Infants ( V260-024 )</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<criteria>Healthy infant least 6 week ( 42 day ) 12 week ( 84 day ) age time first study vaccination Parent/legal guardian agree participate give write informed consent willing able comply study requirement History congenital abdominal disorder , prior rotavirus gastroenteritis , chronic diarrhea , failure thrive , abdominal surgery History intussusception Impairment immunological function , include Severe Combined Immunodeficiency ( SCID ) Acute disease , severe chronic disease , chronic disease acute period Uncontrolled epilepsy , encephalopathy , seizure , progressive neurological disease Hypersensitivity component rotavirus vaccine , OPV , DTaP Prior receipt rotavirus vaccine Fever , axillary temperature &gt; =37.5 °C ( equivalent ) within 24 hour study vaccination ( study vaccination defer complete resolution febrile illness ) Clinical evidence active gastrointestinal illness Received intramuscular , oral , intravenous corticosteroid treatment since birth ( topical , ophthalmic , inhaled steroid permit ) Resides household immunocompromised person Receipt blood transfusion blood product , include immunoglobulin Participation another interventional study within 14 day first study vaccination study Receipt investigational nonregistered product study vaccine within 30 day first study vaccination study For participant immunogenicity arm : inability obtain blood specimen randomization visit ( note : visit may reschedule baseline specimen may obtain ) ; history polio , diphtheria , tetanus , pertussis disease ; previous vaccination diphtheria , tetanus , pertussis , poliomyelitis Any condition , opinion investigator , may interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>